-
This Biotech Is Targeting Indications Worth $70 Billion
Friday, December 22, 2023 - 2:30pm | 192Read More...Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) was recently a guest on Benzinga’s All-Access. ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs...
-
ZyVersa: This Drug Maker Is Targeting Critical Diseases With Novel Approaches
Thursday, April 20, 2023 - 8:49am | 211Read More...Steve Glover, Co-Founder, Chairman, CEO, & President of ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA), was recently a guest on Benzinga’s All-Access. ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs...
